Grant of Options
08 November 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that upon the recommendation of the Company's Remuneration Committee it has granted options over a total of 1,410,750 ordinary shares of £0.00037 in the capital of the Company (the “Ordinary Shares”) to certain employees of the Company pursuant to the terms of the Company’s Stock Option Plan (the “Share Options”).
1,200,000 Share Options have been granted to Mr. Alexander Dusek, the Company’s recently appointed Vice-President of Commercialisation. These Share Options will be exercisable at a price of 23p. 300,000 of the Share Options will vest on 23 October 2020 with the remaining 900,000 Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 30 November 2020.
The remaining 210,750 Share Options will be exercisable at a price of 23p, with 25% of the options vesting on 3 June 2020 and the remaining 75% of the options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 July 2020.
Following the grant of the Share Options referred to above, there are 22,445,072 outstanding options and warrants over Polarean's Ordinary Shares, representing 16.4% of the Company's Ordinary Shares and total voting rights on a fully diluted basis.
|Polarean Imaging plc||www.polarean.com/www.polarean-ir.com|
|Richard Hullihen, Chief Executive Officer||Via Walbrook PR|
|Richard Morgan, Chairman|
|SP Angel Corporate Finance LLP||Tel: +44 (0)20 3470 0470|
|David Hignell / Soltan Tagiev (Corporate Finance)|
|Vadim Alexandre / Rob Rees (Corporate Broking)|
|Walbrook PR||Tel: +44 (0)20 7933 8780
|Anna Dunphy / Paul McManus||Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893|
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|1.||Details of the person discharging managerial responsibilities/person closely associated|
|2.||Reason for the notification|
|a)||Position/status:||Vice-President of Commercialization (PDMR, non-board role)|
|b)||Initial notification/Amendment:||Initial notification|
|3.||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|a)||Name:||Polarean Imaging Plc|
|4.||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)||Description of the financial instrument, type of instrument:
|Options over ordinary shares of £0.00037
|b)||Nature of the transaction:||Grant of options over ordinary shares|
|c)||Price(s) and volume(s):||
|e)||Date of the transaction:||2019-11-06|
|f)||Place of the transaction:||Outside a trading venue|
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.
The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.